Related by context. All words. (Click for frequent words.) 62 Dyloject 61 Zerenex 61 QNEXA 61 Northera 60 aflibercept 59 MoxDuo IR 59 vernakalant 59 oxymorphone ER 59 M6G 59 NicOx 59 Rhucin 59 Orazol 58 Exforge 58 Locteron 58 torezolid phosphate 58 pivotal Phase III 58 tanespimycin 58 BYDUREON 58 alvimopan 58 MAA submission 58 bazedoxifene 58 ELACYT 58 PREOS R 58 PREOS 58 bifeprunox 58 Amigal 57 teduglutide 57 brentuximab vedotin 57 Rhucin ® 57 elotuzumab 57 bicifadine 57 mipomersen 57 Arixtra 57 teriflunomide 57 LEVADEX 57 LibiGel ® 57 Dacogen injection 57 Ereska 57 AZILECT ® 57 EndoTAG TM -1 57 GFT# 57 custirsen 57 RG# [001] 57 Ambrisentan 57 Telaprevir 57 BLA submission 57 phase IIb 57 Adlea 57 Icatibant 57 Ceplene 57 Lodotra 57 PhosLo 57 Ranexa 56 picoplatin 56 ponatinib 56 eltrombopag 56 Cladribine Tablets 56 rhThrombin 56 Nasulin 56 Loramyc ® 56 Zelrix 56 Rhucin R 56 arzoxifene 56 Amrubicin 56 Azedra 56 almorexant 56 oral rivaroxaban 56 exenatide 56 active comparator 56 BAY #-# 56 tolerability profile 56 BLA filing 56 INCB# [002] 56 fidaxomicin 56 ALGRX 56 diabetic neuropathic pain 56 Trexima 56 Bronchitol 56 tipranavir 56 pitavastatin 56 ofatumumab 56 Androxal 56 placebo controlled clinical trials 56 rivaroxaban 56 peginesatide 56 Phase 2b study 56 apremilast 56 avanafil 56 Contrave 55 Bicifadine 55 oral ridaforolimus 55 NEBIDO 55 XIAFLEX 55 microplasmin 55 ambrisentan 55 PS# [001] 55 phase IIa clinical 55 Archexin 55 clevidipine 55 enzastaurin 55 ARCOXIA 55 BAL# [002] 55 exenatide once 55 RSD# 55 ularitide 55 Phase #b/#a 55 BCX# 55 Advagraf 55 cannabinor 55 SUCCEED trial 55 Phase IIa trial 55 Menerba 55 phase IIa 55 eniluracil 55 balsalazide tablet 55 Taxotere R 55 Phase IIb 55 prucalopride 55 Phenoptin 55 ISIS # 55 lurasidone 55 faropenem 55 OLEPTRO TM 55 ridaforolimus 55 albinterferon alfa 2b 55 ThGRF 55 PROMACTA 55 Dyloject TM 55 dose cohort 55 ATryn R 55 efficacy tolerability 55 RhuDex ® 55 Tekturna HCT 55 indiplon capsules 55 ONGLYZA 55 BENLYSTA 55 PLK1 SNALP 55 Proellex TM 55 CIMZIA TM 55 Trizytek 55 NVA# 55 JAK inhibitor 55 dalbavancin 55 AMR# 55 Firazyr 55 Phase III clinical 55 forodesine 55 SNT MC# 55 silodosin 55 JANUVIA 55 ganetespib 55 Dacogen 55 brivaracetam 55 Phase IIb clinical 55 AEGR 55 PRT# 55 Corlux 55 Phase III trials 55 viral kinetic 55 Adcirca 55 iloperidone 54 tezampanel 54 Panzem R NCD 54 SPIRIVA HandiHaler 54 NDA submission 54 Loramyc 54 celgosivir 54 SEROQUEL XR 54 zileuton CR 54 ruxolitinib 54 Acetavance 54 Pirfenidone 54 Zometa zoledronic acid 54 Vernakalant 54 oral FTY# 54 Androxal ® 54 rhC1INH 54 Valdoxan 54 Olmesartan 54 AMRIX 54 INTERCEPT platelets 54 placebo controlled Phase 54 Flutiform 54 WILEX 54 Azilect ® 54 ProSavin 54 Junovan 54 QAB# 54 eprotirome 54 registrational 54 safinamide 54 CIMZIA ™ 54 Diamyd ® 54 Targretin 54 Joulferon 54 CIP ISOTRETINOIN 54 TMC# [002] 54 MERLIN TIMI 54 YONDELIS 54 HuMax CD# 54 Cimzia 54 QRxPharma 54 THALOMID 54 Octreolin 54 Asentar 54 aclidinium 54 INCB# [001] 54 Galvus 54 obatoclax 54 Fortigel 54 regadenoson 54 dacetuzumab 54 Vasovist 54 Desmoteplase 54 Linjeta TM 54 Phase III 54 clinical pharmacology studies 54 atacicept 54 REMINYL ® 54 blinatumomab 54 SILENOR 54 tocilizumab 54 Ketotransdel 54 DDP# 54 PRECiSE 54 ZEGERID Capsules 54 pivotal Phase 54 carfilzomib 54 VEGF Trap 53 vernakalant oral 53 QNEXA ® 53 Riquent 53 PF # [001] 53 KRN# 53 XL# [003] 53 Androxal TM 53 dabigatran etexilate 53 Tekamlo 53 Ruconest 53 DU #b 53 Solzira 53 ASA# 53 perifosine 53 EXPAREL ™ 53 Pennsaid R 53 Phase 2b 53 Phase IIB 53 Gabapentin GR 53 NP2 Enkephalin 53 Fludara 53 L MTP PE 53 Genasense 53 nonclinical studies 53 Civacir 53 OPAXIO 53 aclidinium bromide 53 Xarelto 53 Cimzia ® 53 Dalbavancin 53 Pixuvri 53 placebo controlled Phase III 53 HZT 53 vilazodone 53 Ventavis 53 Onbrez Breezhaler 53 indacaterol 53 glufosfamide 53 HuMax EGFr 53 aleglitazar 53 Fibrillex TM 53 SCHWARZ PHARMA 53 ADVEXIN 53 ferumoxytol 53 OFIRMEV 53 GEM OS1 53 adecatumumab 53 tolerability profiles 53 posaconazole 53 Seroquel XR 53 Phase 1b 53 favorable tolerability 53 CRx 53 CRMD# 53 Lupuzor 53 TBC# 53 BEMA TM Fentanyl 53 SILENOR TM 53 Loramyc R 53 Hycamtin 53 Phase IIb trial 53 ALKS 53 Guerbet 53 vernakalant hydrochloride 53 methylnaltrexone 53 IMA# 53 romidepsin 53 ANA# 53 tesmilifene 53 pharmacokinetic 53 EFAPROXYN 53 GSK# [001] 53 RSD# iv 53 romiplostim 53 Sular formulation 53 alogliptin 53 Genentech Roche 53 Xinlay 53 TKM ApoB 53 TRISENOX 53 ILLUMINATE 53 iniparib 53 valopicitabine 53 edoxaban 53 pharmacodynamic properties 53 Phase IIIb clinical 53 iclaprim 53 Alpharadin 53 clevudine 53 pazopanib 53 FTY# 53 NUVIGIL 53 DASISION 53 Zemiva 53 TEMODAL 53 palifosfamide 53 linaclotide 53 axitinib 53 COMFORT II 53 Frova ® 53 zalutumumab 53 LAF# 53 pradefovir 53 rNAPc2 53 Phase 1b trial 53 Phase IIa trials 53 Nebido 53 GATTEX 53 MOZOBIL 53 PRX # 53 sunitinib malate 53 sapacitabine 53 ILUVIEN ® 53 Phase IIa clinical 53 telaprevir 53 phase IIb clinical 53 PHX# 53 omecamtiv mecarbil 53 DYNEPO 53 CDP# 53 Genz # 53 nalbuphine ER 53 lomitapide 53 cethromycin 53 Onrigin 53 elinogrel 53 vidofludimus 53 Pruvel 53 orBec 53 AZX# 53 oral diclofenac 53 mertansine 53 BEMA Buprenorphine 52 ALTU 52 XGEVA 52 AeroLEF TM 52 lesinurad 52 LCP AtorFen 52 Santhera 52 MIRCERA 52 RSR# 52 R#/MEM # 52 intravenous acetaminophen 52 saxagliptin 52 pomalidomide 52 danoprevir 52 ZOLINZA 52 Aptivus 52 Itopride 52 LEVADEX ™ 52 voclosporin 52 Albuferon 52 pafuramidine 52 Adenuric R 52 Neulasta ® 52 CoFactor 52 sorafenib tablets 52 lixisenatide 52 lumiliximab 52 Phase III clinical trials 52 QVA# 52 CAELYX 52 Plicera 52 Phase 2b clinical trials 52 Tyvaso 52 elagolix 52 pharmacokinetic studies 52 EOquin 52 Rebif ® 52 ocrelizumab 52 tamibarotene 52 pralatrexate 52 Sym# 52 Coreg CR 52 Traficet EN 52 Hematide 52 vosaroxin 52 Plenaxis TM 52 HuMax CD4 52 Solulin 52 Increlex R 52 IV APAP 52 BioAlliance Pharma 52 asenapine 52 Restanza 52 LymphoStat B 52 AZILECT R 52 Relovair 52 ADVANCE PD 52 primary efficacy endpoints 52 Omigard 52 ELADUR 52 Vidaza 52 Celgene Revlimid 52 PROSTVAC TM 52 Certriad 52 DCCR 52 Ophena TM 52 Phase Ib study 52 Phase Ib 52 placebo controlled studies 52 Anturol ® 52 ceftobiprole 52 lubiprostone 52 CaPre TM 52 Dapagliflozin 52 durable pain palliation 52 Marketing Authorisation Application MAA 52 sNDA submission 52 tivozanib 52 Relivar 52 TELCYTA 52 Oracea 52 Viramidine 52 Glybera R 52 AVADO 52 AzaSite Plus 52 ThermoDox ® 52 Phase IIa 52 azficel T 52 Bifeprunox 52 LCP Tacro 52 lanthanum carbonate 52 CIP TRAMADOL ER 52 frovatriptan 52 fostamatinib 52 ONGLYZA ™ 52 PDE4 inhibitor 52 Nexavar 52 Kuvan 52 Flutiform TM 52 Onrigin TM 52 goserelin 52 roflumilast 52 talactoferrin 52 bosutinib 52 bovine thrombin 52 satraplatin 52 pharmacodynamic effects 52 Advexin 52 Phase #/#a 52 LIALDA 52 OvaRex ® MAb 52 vandetanib 52 Ostarine 52 dapagliflozin 52 thymalfasin 52 cetrorelix 52 Arikace 52 budesonide MMX 52 Synavive 52 SABCS 52 Phase 2a trial 52 dimebon 52 indibulin 52 glatiramer acetate 52 Zenvia Phase III 52 eculizumab 52 Hsp# inhibitor 52 Serdaxin 52 rFIXFc 52 Orathecin 52 metaglidasen 52 Mycamine 52 MoxDuo ® IR 52 Tavocept 52 MGCD# [001] 52 Allovectin 7 52 Tracleer 52 Fx #A 52 Soliris TM eculizumab 52 daclizumab 52 Marqibo 52 analgesic efficacy 51 Lialda 51 Marketing Authorization Application MAA 51 ORENCIA ® 51 riociguat 51 LIVALO 51 Serdolect 51 PEG PAL 51 Fodosine 51 thorough QT 51 EOquin TM 51 Tracleer r 51 Rezular 51 rALLy trial 51 pegloticase 51 BrachySil TM 51 phase IIb trial 51 Biopartners 51 cladribine tablets 51 atrasentan 51 baminercept 51 ozarelix 51 Zebinix R 51 subcutaneously administered 51 Debio 51 Stimuvax R 51 oral calcitonin 51 PRIMO CABG 51 pegylated interferons 51 Lu AA# 51 Alocrest 51 Evoltra 51 pharmacodynamic 51 ANCHOR trial 51 otelixizumab 51 CORLUX 51 NDA resubmission 51 clazosentan 51 IRX 2 51 Avastin bevacizumab 51 Nexavar ® 51 randomized multicenter Phase III 51 Phase 1a 51 favorable pharmacokinetic profile 51 dose cohorts 51 Phase 2b clinical 51 pharmacokinetics pharmacodynamics 51 desvenlafaxine 51 ATPace TM 51 #mg dose [001] 51 liprotamase 51 acyclovir Lauriad R 51 Oral NKTR 51 FOLOTYN 51 oral fludarabine 51 BRIM3 51 INT# [002] 51 FOSRENOL 51 Phase 2b trial 51 Fablyn 51 Vilazodone 51 bardoxolone 51 Bydureon 51 fenofibrate 51 incyclinide 51 Cloretazine R VNP#M 51 SYCREST 51 rEV# 51 veltuzumab 51 Neurodex 51 darapladib 51 Plenaxis R 51 PRE SURGE 51 luliconazole 51 Promacta 51 BENLYSTA ® 51 Cimzia ® certolizumab pegol 51 TRO# 51 Angiox 51 Treanda 51 Nanobody 51 Proxinium TM 51 maribavir 51 ACTEMRA 51 metastatic HRPC 51 tezampanel NGX# 51 GLPG# 51 RE LY ® 51 oral deforolimus 51 Anturol TM 51 Hyphanox 51 CR# vcMMAE 51 Cleviprex TM clevidipine 51 mg doses 51 Phase 2a 51 Myocet 51 cariprazine 51 Exalgo 51 Frova R 51 Preos 51 Anturol 51 tecarfarin 51 Phase Ib II 51 mg dose 51 interferon gamma 1b 51 fesoterodine 51 desvenlafaxine succinate 51 Entereg 51 adipiplon 51 FIRAZYR 51 Actelion 51 BST CarGel R 51 sitaxsentan 51 LymphoStat B belimumab 51 Levadex 51 Zalbin 51 tasimelteon 51 CLARITY study 51 Factive 51 interferon beta 1b 51 leading oral taxane 51 Elocalcitol 51 oral prodrug 51 tasocitinib 51 pioglitazone HCl 51 RoACTEMRA 51 Thelin tm 51 alvespimycin 51 neratinib 51 PROVENGE sipuleucel T 51 DP b# 51 Trofex 51 anidulafungin 51 clinical trial 51 MEPACT 51 RSD# oral 51 SILENOR ™ 51 Cimzia TM 51 telbivudine 51 Tracleer R 51 Chrysalin 51 bremelanotide 51 elvucitabine 51 deforolimus 51 azacitidine 51 ORENCIA R 51 Actemra 51 Valtropin 51 Nycomed 51 Dasatinib 51 ticagrelor 51 GLYX 51 BioAlliance 51 randomized Phase 51 Panzem 51 sBLA 51 TG MV 51 GetGoal Phase III 51 PSN# [002] 51 EVIZON 51 Dual Opioid 51 preclinical efficacy 51 Protelos 51 Raptiva R 51 Renvela 51 maximally tolerated dose 51 tolevamer 51 confirmatory Phase 3 51 Biologics License Application BLA 51 Stedivaze 51 Sebivo 51 Milnacipran 51 pharmacokinetic equivalence 51 DAVANAT R 51 PXD# 51 including eniluracil ADH 51 multicenter Phase 51 intermittent dosing 51 Lixisenatide 51 Ketotransdel ® 51 Azedra TM 51 SPARLON 51 dose escalation 51 SUTENT ® 51 trabectedin 51 Tovaxin 51 eszopiclone 51 Intermezzo R 51 dosing cohort 51 Randomized Phase 51 NKTR 51 Oncophage 51 paliperidone ER 51 Preotact 51 relapsed multiple myeloma 51 Insegia 51 phase Ib 51 Canvaxin 50 APPRAISE 50 mesylate tablets 50 ACTEMRA TM 50 Taxotere ® 50 PAION 50 Flutiform ™ 50 GRAVITAS trial 50 Tasigna nilotinib 50 Augment Injectable 50 Bepreve 50 IND submission 50 Aptivus ® 50 cediranib 50 L BLP# 50 febuxostat 50 Pimavanserin 50 proprietary transdermal patch 50 CAPHOSOL 50 Qnexa 50 fidaxomicin Phase 50 APF# 50 OncoVEX GM CSF 50 Raptiva ® 50 virus HCV protease inhibitor 50 FTY# fingolimod 50 Alzhemed TM 50 Aplidin 50 Mipomersen 50 AVE# 50 NO# [002] 50 TPI ASM8 50 Phoqus 50 Zavesca r 50 IV Busulfex 50 ONCONASE 50 Sanctura XR 50 peginterferon alfa 2b 50 T Pred 50 dose escalation trial 50 Remodulin 50 secondary efficacy endpoints 50 Alvesco R 50 dose regimens 50 ATryn ® 50 RHUCIN 50 Dificid 50 ALD# 50 Factor Xa inhibitor 50 TOCOSOL Paclitaxel 50 Stelara 50 IDX# 50 subcutaneous formulation 50 FACTIVE R gemifloxacin 50 #D#C# 50 Acapodene 50 midstage studies 50 ADAGIO study 50 Phase #/#a trial 50 ecallantide 50 Virulizin ® 50 toremifene 50 Augment Bone Graft 50 opioid induced bowel dysfunction 50 Intermezzo ® 50 rasagiline tablets 50 NeoVisc 50 taspoglutide 50 TYKERB 50 octreotide acetate 50 BRILINTA 50 Prosaptide 50 linagliptin 50 APTIVUS 50 MYDICAR 50 GATTEX ® 50 ixabepilone 50 ABILIFY R 50 MoxDuo 50 VPRIV 50 phase 2a 50 Varisolve 50 Increlex ® 50 Sancuso 50 pharmacokinetic PK 50 Lung Rx 50 TroVax 50 panitumumab 50 Tarceva erlotinib 50 Balaglitazone 50 MabThera rituximab 50 AERx iDMS 50 FM VP4 50 regorafenib 50 Marketing Authorization Applications 50 oritavancin 50 placebo controlled trials 50 crizotinib PF # 50 sulodexide 50 Theratope 50 Æterna Zentaris 50 ICA # 50 EndoTAG 50 BEXXAR 50 Cetrorelix 50 lorcaserin Phase 50 GEM OS2 50 AGGRASTAT R 50 omacetaxine 50 MAGE A3 ASCI 50 oral methylnaltrexone 50 Excellagen 50 Antegren 50 ENDEAVOR IV 50 TREANDA 50 efficacy 50 Targretin capsules 50 fipamezole 50 REYATAZ R 50 Aryplase 50 Quinamed 50 Yondelis 50 CB2 selective receptor agonist 50 Alvesco 50 Fampridine SR 50 topical NSAID 50 rilonacept 50 Folotyn 50 randomized controlled clinical trials 50 bosentan 50 tolerability 50 Avanafil 50 pirfenidone 50 MEND CABG 50 Aurexis 50 Tarceva TM 50 GAMMAGARD 50 Q#IR 50 vicriviroc 50 C1 INH 50 confirmatory Phase III 50 histone deacetylase HDAC inhibitor 50 investigational drug 50 Phase IIb trials 50 Torisel 50 Phase 2a clinical 50 MNTX 50 sunitinib 50 Nexavar sorafenib 50 severe hypercholesterolemia 50 phase IIb study 50 DURATION 50 PrevOnco 50 DAVANAT 50 SAR# [004] 50 AEG# 50 oral taxane 50 HoFH 50 Kynapid 50 bioequivalence 50 acyclovir Lauriad ® 50 Phase III pivotal 50 sevelamer carbonate 50 TRANSDUR Sufentanil 50 liraglutide 50 Microplasmin 50 Degludec 50 Qutenza 50 Phase IIb clinical trials 50 Prestara 50 Firdapse 50 efficacy endpoint 50 Emselex 50 Orencia 50 LY# [003] 50 eprodisate Fibrillex TM 50 lasofoxifene 50 midstage clinical 50 indiplon 50 tesetaxel 50 Probuphine 50 Allovectin 7 ® 50 Zavesca 50 RoActemra 50 COPAXONE R 50 GLP1 agonist 50 Exelixis compounds 50 ARIKACE 50 Cellegesic 50 Menarini 50 ORMD 50 Ceplene R 50 ATL# [001] 50 Marketing Authorisation Application 50 AQ4N 50 ProLindac 50 Pennsaid 50 PEG Interferon lambda 50 Invicorp R 50 CCR9 antagonist 50 RE SURGE 50 Genasense R oblimersen 50 urate lowering 50 Marketing Authorization Application 49 PEG SN# 49 phase IIIb 49 COPAXONE ® 49 HepeX B 49 ACOMPLIA R 49 Stavzor 49 comparator arm 49 Saforis 49 Benlysta belimumab 49 pharmacodynamic profile 49 Panzem R 49 StaphVAX 49 urocortin 2 49 RELOVAIR ™ 49 FlutiformTM 49 tafamidis 49 ATPace 49 Zenvia 49 MAP# 49 Pivotal Phase III 49 clinical trials 49 selective androgen receptor modulator 49 Blopress 49 miconazole Lauriad ® 49 Biologic License Application BLA 49 FDA Approvable Letter 49 pharmacokinetic profile 49 Shigamabs ® 49 Treximet 49 VELCADE 49 TriLipix 49 LEXIVA r 49 ceftaroline 49 Phase IIb III 49 Aclidinium 49 insulin degludec 49 FOSRENOL ® 49 Triolex 49 Aegerion 49 Zipsor 49 Somatuline R Autogel R 49 DepoDur 49 betrixaban 49 NGX# 49 calcitonin 49 NOX E# 49 GALNS 49 ISENTRESS 49 tipifarnib 49 Phase III Clinical Trials 49 NXL# 49 Initiated Phase 49 sNDA 49 Zyflo 49 ABILIFY ® 49 CLORETAZINE TM VNP#M 49 isatoribine 49 Phase 1b dose escalation 49 prasugrel 49 Pharmacokinetic parameters 49 Virulizin R 49 FOLOTYN ® 49 Juvista 49 PSN# [001] 49 elacytarabine 49 dose escalation Phase 49 PIX# [002] 49 investigational hepatitis C 49 Allovectin 7 R 49 Exelbine 49 randomized Phase 2b 49 TORISEL 49 VIDAZA 49 Tesamorelin 49 vorinostat 49 Photocure 49 Mepact 49 ADX# 49 PegIntron 49 Amplimexon 49 CYT# 49 DPP4 inhibitor 49 Ixempra 49 ruboxistaurin 49 nimotuzumab 49 lintuzumab 49 multicenter Phase III 49 BRIM2 49 subcutaneous RELISTOR 49 Carfilzomib 49 Triapine R 49 Celacade TM technology 49 Romidepsin 49 TMC# [001] 49 ofatumumab HuMax CD# 49 ZALBIN